Mini-midlines exist to fill the gap between short peripheral IVs and full midline/PICC lines by providing safer, longer-lasting peripheral access about 1–4 weeks for appropriate infusates, while avoiding the risks, costs, and invasiveness of central venous catheters.
Primary clinical need
Mini-midlines are designed for patients who need more than a few days of IV therapy but do not require central venous access, offering longer dwell times than short peripheral IVs with fewer re-sticks and less venous damage. They are typically used for non‑vesicant, peripherally compatible medications and fluids with moderate osmolarity and pH, where central lines would be excessive and short cannulas fail or repeatedly infiltrate.
Problems they are solving
High failure and replacement rates of short peripheral IVs lead to repeated venipuncture, vein depletion, therapy interruption, and patient discomfort, particularly in difficult IV access (DIVA) patients.
Central venous devices (e.g., PICCs) carry higher risks of central line–associated infections and more invasive insertion, making them unsuitable for medium term therapies that can be delivered peripherally.
How Mini-Midlines address those needs
Mini-midlines often 8–10 cm, upper arm or forearm can remain in place 1–4 weeks, reducing the number of cannulations and associated complications while maintaining reliable access. They tend to be less invasive, lower cost, and associated with fewer serious complications such as bloodstream infections compared with PICCs, while also reducing phlebitis and infiltration versus repeated short IVs when used appropriately.
Typical patient and therapy scenarios
Mini-midlines are particularly useful for patients with poor peripheral veins, frequent blood draws or venipuncture, and anticipated IV therapy of about 7 days to 4 weeks using non‑vesicant antibiotics, hydration, or electrolyte solutions within recommended osmolarity and pH ranges. They can also serve as interim access while awaiting definitive long‑term access, especially in acute care, ICU, post‑surgical, and some home infusion settings where repeated peripheral IV failure is common but central access is not strictly indicated.
Mini-midlines fill an important gap in vascular access, offering a reliable, safer, and cost-effective solution for patients who need medium-term IV therapy without the risks and invasiveness of central lines. By providing longer dwell times than short peripheral IVs and reducing complications such as repeated venipuncture, infiltration, and phlebitis, they improve patient comfort and therapy continuity. Appropriate use of mini-midlines ensures effective peripheral access for non‑vesicant, peripherally compatible medications, making them a valuable option in both acute and home care settings.
Explore our ProV Midline ST Catheter, customized to meet your unique requirements with a variety of configurations. Designed to satisfy the needs of both medical professionals and patients, our vascular access devices stand out as the best option. Please contact us today for more information about our products and for a custom quotation.
Health Line International Corp. is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. This content is not intended to replace professional medical advice.
References:
Nickel, B. et al., (2024, January/ February) Infusion Therapy Standards of Practice 9th edition. Journal of Infusion Nursing. https://www.ins1.org/publications/infusion-therapy-standards-of-practice/
Urtecho, M. et al., (2023, January 18) Comparing Complication Rates of Midline Catheter vs Peripherally Inserted Central Catheter. A Systematic Review and Meta-analysis. National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC9898877/
Irisneida, M. et al., (2018, March 20) Mini-Midline a New device for Peripheral Venous Catheterization UN Emergency Wards. Juniper Publishers. https://juniperpublishers.com/jaicm/pdf/JAICM.MS.ID.555678.pdf